Regeneron and its “VELOCISUITE®” platform was used to develop a treatment for Ebola (REGN-EB3), currently used by the Congolese government to fight that horrific virus. The New York State-based venture has, like many biopharma companies, dedicated a full force operation to target COVID-19. In a 24X7 operation, the company reports “sleepless nights” and “headway” toward a potential vaccine. After initiating hundreds of virus-neutralizing antibodies, they have declared public plans to initiate large-scale manufacturing by mid-April with antibody cocktail therapy with the potential to commence human clinical trials by early summer.
In addition to collaborating with Sanofi (a French pharmaceutical company) to repurpose a drug (Kevzara®) that could address conditions experienced by COVID-19 patients, the company appears to be making notable progress in its mission to find a vaccine for the novel coronavirus. TrialSite News breaks down this information, offered by Regeneron via their press release, so that hopefully more people can have a better understanding of the current situation.
Who heads up their COVID-19 R&D?
Christos Kyratsous, PhD, Vice Preside...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).